EC approves Boehringer Ingelheim and Lilly’s Jardiance for CKD treatment
The EC’s approval is based on results from the EMPA-KIDNEY trial in which Jardiance reduced the relative risk…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Jul 23
The EC’s approval is based on results from the EMPA-KIDNEY trial in which Jardiance reduced the relative risk…
26 Jul 23
The FDA’s approval was based on the findings of Saturn-1 and Saturn-2 trials in which XDEMVY showed considerable…
25 Jul 23
According to the conditions of the exchange offer, Johnson & Johnson’s shareholders can trade all, some, or none…
25 Jul 23
Upon conclusion of the deal, Quince will fund the EryDex through the Phase 3 clinical trial under special…
25 Jul 23
The study used five validated scoring tools that assessed health-related quality of life components, in which participants reported…
25 Jul 23
The authorizations are based on Phase 2b trial results published in The Lancet Infectious Diseases, as well as…
24 Jul 23
Ycanth is a drug-device combination that contains a formulation of cantharidin (0.7%w/v) delivered through a single-use applicator, for…
24 Jul 23
The Phase 3 ENHANCE trial is a randomised, double-blind study that was intended to assess the combination of…
24 Jul 23
The company intends to further extend its global reach, which has been focused on Southeast Asia and Latin…
24 Jul 23
EMA’s Committee for Medicinal Products for Human Use (CHMP) supported the approval based on the data from two…